Release date: 11 February 2020
Promoter – Financial Intermediary
The promoter is a biotech company pioneering the development of next generation of personalised immunotherapies for oncology and other diseases. The project relates to research and development (R&D) investments for the development of cancer patient-tailored therapeutic vaccines, based on break-through proprietary platforms.
The project falls within the scope of the Horizon 2020 programme Societal Challenges (Health, Demographic Change and Wellbeing).
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 50 million
Total cost (Approximate amount)
EUR 100 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details will verified during the appraisal, to ensure they are aligned with best practices.
The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if after the project appraisal the EIB were to conclude that the promoter is after all subject to EU public procurement legislation 2014/24/EU where applicable, then the Bank would require the promoter to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation Directive 2014/24/EU, where applicable, as well as Directive 89/665/EEC as interpreted by the Court of Justice of the EU, with the publication of tender notices in the Official Journal of the EU, as and where required.
Signed - 12/12/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).